Voluntis, a Paris, France-based therapeutic companion software, closed a €20.75m ($29m) Series D financing.
The round was co-led by Bpifrance and Innovation Capital, with participation from Vesalius Biocapital, Qualcomm, through its venture capital arm, Qualcomm Ventures, and existing investors CapDecisif Management, CM-CIC Capital Innovation and Sham.
The company intends to use the funds to accelerate the development of its diabetes management solution, advance new programs in other chronic diseases and ramp up its US operations.
Founded in 2001 by Pierre Leurent, CEO, Voluntis develops proprietary companion software dedicated to managing chronic conditions such as diabetes, anticoagulation and hemophilia. In diabetes, its Voluntis Insulin Therapy Manager (VITM) is developed to support patients across the insulin pathway.
The company, which also has offices in Boston, USA, also provides partners with development and regulatory capabilities to elaborate their own digital solution based upon its core system architecture.